FNIH Biomarkers Consortium Confirms Blood Tests Provide a Key Research Tool for Measuring Amyloid Accumulation in Alzheimer’s Disease

North Bethesda, MD, July 26, 2021—The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has evaluated several blood tests that can detect one of the known characteristics of Alzheimer’s disease (AD).

Three Questions with Sarcopenia 2 Principal Investigators Dr. Shalender Bhasin and Dr. Peggy Cawthon

 September 21, 2020 — The FNIH Biomarkers Consortium Sarcopenia 2 project, Sarcopenia as a Valid Biomarker for Identifying Individuals at Risk of Disability, recently achieved the key milestone of publishing seven articles in The Journal of the American Geriatrics Society and The Journals of Gerontology

The FNIH Earns Coveted Four-Star Rating from Charity Navigator for Sixth Consecutive Year

June 8, 2020  — For the sixth year in a row, the Foundation for the National Institutes of Health (FNIH) has earned the top designation of four-star honors from the nation’s largest independent charity evaluator, Charity Navigator. Only 9 percent of charities evaluated by the group have received this highest rating for at least six consecutive years, indicating that the FNIH “outperforms most charities in America.”

FNIH Launches Project Testing Antibiotic to Prevent Infections in Mothers and Newborns

June 3, 2020 – The Foundation for the National Institutes of Health (FNIH) has announced a new project that will test whether an antibiotic taken during labor can prevent infections in mothers and newborns in seven low- and middle-income countries. This study will be conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) through their Global Network for Women’s and Children’s Health Research (Global Network) with funding from the Bill & Melinda Gates Foundation.

FNIH Biomarkers Consortium NIMBLE Project Receives FDA Nod to Move Forward in Biomarker Qualification

May 15, 2020 — The FNIH Biomarkers Consortium program Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) has received acceptance from the U.S. Food and Drug Administration (FDA) for its Letter of Intent (LOI). NIMBLE seeks to qualify biomarkers to easily diagnose clinically significant non-alcoholic steatohepatitis, or NASH.